Dear Sir/Madam

On behalf of the British Uro-oncology Group (BUG) please find below our comment with regard to the above ACD. I would be grateful if you would confirm receipt and that you do not require anything further from us at this point in time.

Thank you.

The British Uro-oncology Group (BUG) supports the proposed availability of enzalutamide on the NHS for patients with mCRPC. However, BUG has the following comments to make with regard to the Appraisal Consultation Document:

In Section 1.1 and 4.8 the recommendation for enzalutamide for patients whose disease has progressed during or after one docetaxel containing chemotherapy regimen excludes patients who have received two or more courses of chemotherapy. BUG challenges the clinical rationale for this exclusion of this subgroup of patients. It is further anticipated that the patient population receiving two or more courses of chemotherapy would be relatively small and would not impact significantly upon the cost of the drug to the NHS. BUG strongly requests NICE to make enzalutamide available for patient who have received one, two or more cycles of chemotherapy regimen.

[redacted]
British Uro-oncology Group (BUG) Secretariat
Right Angle
Barley Mow Centre, 10 Barley Mow Passage
London W4 4PH

[redacted]